Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the...
Uloženo v:
| Vydáno v: | The Lancet (British edition) Ročník 373; číslo 9670; s. 1183 - 1189 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Kidlington
Elsevier Ltd
04.04.2009
Elsevier Elsevier Limited |
| Témata: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment.
We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15–20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant
Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with
ClinicalTrials.gov, number
NCT00082173.
74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17·2%, 95% CI 2·8–31·7; p=0·03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group).
Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified.
US Food and Drug Administration Office of Orphan Product Development, with additional support from the US National Institutes of Health. |
|---|---|
| AbstractList | New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173. 74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified. Summary Background New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. Methods We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15–20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov , number NCT00082173. Findings 74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17·2%, 95% CI 2·8–31·7; p=0·03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). Interpretation Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified. Funding US Food and Drug Administration Office of Orphan Product Development, with additional support from the US National Institutes of Health. Background New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. Methods We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173. Findings 74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). Interpretation Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified. New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment.BACKGROUNDNew treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment.We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173.METHODSWe undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173.74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group).FINDINGS74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group).Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified.INTERPRETATIONMoxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified. New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15–20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173. 74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17·2%, 95% CI 2·8–31·7; p=0·03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified. US Food and Drug Administration Office of Orphan Product Development, with additional support from the US National Institutes of Health. New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment. We undertook a phase II, double-blind, randomised controlled trial of a regimen that included moxifloxacin in adults with sputum smear-positive tuberculosis at one hospital in Rio de Janeiro, Brazil. 170 participants received isoniazid, rifampicin, and pyrazinamide at standard doses and were assigned by permuted block randomisation to receive either moxifloxacin (400 mg) with an ethambutol placebo (n=85) or ethambutol (15-20 mg/kg) plus moxifloxacin placebo (n=85) 5 days per week for 8 weeks. The primary endpoint was the proportion of patients whose sputum culture had converted to negative by week 8. Analysis was by modified intention to treat (ITT); patients whose baseline cultures were negative, contaminated, or contained drug-resistant Mycobacterium tuberculosis were excluded from the analysis. Additionally, all missing 8-week results were deemed treatment failures. This study is registered with ClinicalTrials.gov, number NCT00082173. 74 patients assigned to the moxifloxacin group and 72 in the ethambutol group were included in the modified ITT population. 125 patients had 8-week data (moxifloxacin n=64, ethambutol n=61); the main reason for absence of data was culture contamination. At 8 weeks, culture conversion to negative had occurred in 59 (80%) of 74 patients in the moxifloxacin group compared with 45 (63%) of 72 in the ethambutol group (difference 17.2%, 95% CI 2.8-31.7; p=0.03). There were 16 adverse events (eight in each group) in 12 patients. Only one event was judged related to study drug (grade 3 cutaneous reaction in the ethambutol group). Moxifloxacin improved culture conversion in the initial phase of tuberculosis treatment. Trials to assess whether moxifloxacin can be used to shorten the duration of tuberculosis treatment are justified. |
| Author | Graça, Nadja P Loredo, Carla Conde, Marcus B Chaudhary, Mohammad A De Souza, Gilvan R Muzy Cezar, Michelle C Ram, Malathi Chaisson, Richard E Bishai, William R Kritski, Afranio L Efron, Anne |
| Author_xml | – sequence: 1 givenname: Marcus B surname: Conde fullname: Conde, Marcus B organization: Instituto de Doencas do Torax/Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 2 givenname: Anne surname: Efron fullname: Efron, Anne organization: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 3 givenname: Carla surname: Loredo fullname: Loredo, Carla organization: Instituto de Doencas do Torax/Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 4 givenname: Gilvan R Muzy surname: De Souza fullname: De Souza, Gilvan R Muzy organization: Instituto de Doencas do Torax/Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 5 givenname: Nadja P surname: Graça fullname: Graça, Nadja P organization: Instituto de Doencas do Torax/Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 6 givenname: Michelle C surname: Cezar fullname: Cezar, Michelle C organization: Instituto de Doencas do Torax/Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 7 givenname: Malathi surname: Ram fullname: Ram, Malathi organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA – sequence: 8 givenname: Mohammad A surname: Chaudhary fullname: Chaudhary, Mohammad A organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA – sequence: 9 givenname: William R surname: Bishai fullname: Bishai, William R organization: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 10 givenname: Afranio L surname: Kritski fullname: Kritski, Afranio L organization: Instituto de Doencas do Torax/Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 11 givenname: Richard E surname: Chaisson fullname: Chaisson, Richard E email: rchaiss@jhmi.edu organization: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21309824$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19345831$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkluL1DAUgIOsuBf9CUoRFAWrJ03TNoqKLF4GVnxQwbeQJqdM1kwzJumy--JvN3NxFwZkfDohfOfj3I7JwehHJOQ-hecUaPPiK9AayqZlzRMQTxtgjJVwixzRuq1LXrc_DsjRNXJIjmM8B4C6AX6HHFLBat4xekR-f_aXdnD-Umk7FhcY4hQLTHO16KfkXZE_0xxzsMkqV6SAKi1wTIUfijT1GPTkfLTxZaEK46feYdk7O5pnRVCj8QsbMb-1H1PwzqEplnMVsZjNsioL75Lbg3IR723jCfn-4f2300_l2ZePs9N3Z6VuoE0ltkrXzHQAPXIhVDO0LaUcK9SgaypaRU2vONfcNAh9rRiqHgXtDGhkA2Un5PHGuwz-14QxyVyZRufUiH6Kssm6jsF-sALOOlF1GXy4A577KYy5CUmFgAq6jmfowRaa-gUauQx2ocKV_Dv_DDzaAipq5YY8NG3jNVdRBqKr6szxDaeDjzHgcKMCuboHub4HuVq2BCHX9yAh573aydM2qWRX-1DW7c1-u8nGvJoLi0FGbXHUaGxAnaTxdq_hzY5B5-uwudWfeIXxZmQyVhI2kpUDxNqwErz-t-A_CvgDqHr3cA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1093_cid_civ911 crossref_primary_10_1586_17476348_2016_1166960 crossref_primary_10_3389_fmed_2025_1596579 crossref_primary_10_1002_cmdc_201000526 crossref_primary_10_1038_s42003_021_02184_0 crossref_primary_10_1056_NEJMoa1407426 crossref_primary_10_1016_j_tube_2015_03_014 crossref_primary_10_1128_JCM_00757_10 crossref_primary_10_1016_j_ejmech_2012_02_033 crossref_primary_10_2217_fmb_13_70 crossref_primary_10_1097_CPM_0b013e3181efa16f crossref_primary_10_1164_rccm_201001_0140UP crossref_primary_10_1186_s12879_015_1205_4 crossref_primary_10_1002_jcph_968 crossref_primary_10_1056_NEJMc1302312 crossref_primary_10_1093_cid_ciz152 crossref_primary_10_1016_S0140_6736_10_60359_9 crossref_primary_10_1371_journal_pone_0125403 crossref_primary_10_1080_10826076_2017_1280680 crossref_primary_10_1093_cid_civ195 crossref_primary_10_1086_678978 crossref_primary_10_1128_JCM_01229_09 crossref_primary_10_1016_S0140_6736_10_60359_5 crossref_primary_10_1164_rccm_201304_0697ED crossref_primary_10_1371_journal_pone_0096389 crossref_primary_10_1126_scitranslmed_abd7618 crossref_primary_10_1128_AAC_00695_11 crossref_primary_10_1164_rccm_200905_0708ED crossref_primary_10_1016_S1473_3099_16_00070_0 crossref_primary_10_1016_S1473_3099_16_30274_2 crossref_primary_10_1097_MCP_0000000000000045 crossref_primary_10_1097_QCO_0000000000000090 crossref_primary_10_1016_j_cmi_2023_07_013 crossref_primary_10_1128_AAC_01474_09 crossref_primary_10_1093_cid_ciu550 crossref_primary_10_1016_j_revmed_2014_05_005 crossref_primary_10_1183_09031936_00176610 crossref_primary_10_1183_09059180_00000511 crossref_primary_10_1007_s10405_010_0404_3 crossref_primary_10_1017_S0950268814003136 crossref_primary_10_1111_jcpt_13555 crossref_primary_10_1093_jac_dkr449 crossref_primary_10_1016_S0140_6736_09_61189_2 crossref_primary_10_1371_journal_pone_0071116 crossref_primary_10_1164_rccm_201712_2524OC crossref_primary_10_1016_S2213_2600_19_30366_2 crossref_primary_10_1111_resp_13345 crossref_primary_10_1183_09031936_00054410 crossref_primary_10_1371_journal_pone_0060531 crossref_primary_10_1155_2013_147565 crossref_primary_10_1097_FTD_0b013e31821b793c crossref_primary_10_1186_s13063_017_1811_0 crossref_primary_10_1016_S0140_6736_09_60559_6 crossref_primary_10_1128_JCM_00231_11 crossref_primary_10_1164_rccm_201212_2328OC crossref_primary_10_1016_j_ccm_2009_08_011 crossref_primary_10_1056_NEJMoa1315817 crossref_primary_10_1073_pnas_1525047113 crossref_primary_10_1016_S0001_4079_19_30635_1 crossref_primary_10_3389_fmicb_2016_00669 crossref_primary_10_1371_journal_pcbi_1005650 crossref_primary_10_3109_09273948_2015_1019155 crossref_primary_10_1016_j_jtbi_2025_112176 crossref_primary_10_1128_AAC_01478_13 crossref_primary_10_1016_j_tube_2015_02_037 crossref_primary_10_1016_j_idnow_2025_105062 crossref_primary_10_4155_ipk_2017_0004 crossref_primary_10_1080_23744235_2016_1195914 crossref_primary_10_1016_j_bmcl_2013_12_080 crossref_primary_10_1002_ppul_22755 crossref_primary_10_1183_09031936_00104209 crossref_primary_10_3904_kjim_2016_31_1_15 crossref_primary_10_1128_AAC_02583_13 crossref_primary_10_1038_emi_2016_12 crossref_primary_10_1128_AAC_05293_11 crossref_primary_10_1007_s10337_016_3224_8 crossref_primary_10_1111_j_1440_1843_2010_01775_x crossref_primary_10_1186_1471_2334_11_255 crossref_primary_10_1371_journal_pone_0018358 crossref_primary_10_1016_j_ijid_2015_10_007 crossref_primary_10_4155_fmc_11_95 crossref_primary_10_1186_s12879_016_2097_7 crossref_primary_10_1186_s12916_016_0565_y crossref_primary_10_1016_j_ijid_2017_05_003 crossref_primary_10_1371_journal_pcbi_1010823 crossref_primary_10_1016_j_cct_2020_105938 crossref_primary_10_1016_S0140_6736_14_62002_X crossref_primary_10_1016_j_ijtb_2020_07_017 crossref_primary_10_1183_09031936_00033010 crossref_primary_10_1016_j_bjid_2013_01_007 crossref_primary_10_1016_j_mmifmc_2025_04_368 crossref_primary_10_1128_AAC_00968_10 crossref_primary_10_26693_jmbs03_02_161 crossref_primary_10_1186_s13063_015_1050_1 crossref_primary_10_1089_jwh_2012_4171 crossref_primary_10_1164_rccm_201501_0069OC crossref_primary_10_1164_rccm_201106_0995PP crossref_primary_10_1371_journal_pone_0151724 crossref_primary_10_1016_S0973_3698_11_60039_3 crossref_primary_10_7861_clinmedicine_11_4_353 crossref_primary_10_1016_S1473_3099_11_70350_4 crossref_primary_10_1371_journal_pone_0012245 crossref_primary_10_1128_AAC_01514_10 crossref_primary_10_1586_eri_10_60 crossref_primary_10_7717_peerj_2053 crossref_primary_10_1186_1471_2288_13_139 crossref_primary_10_1016_j_jchromb_2011_03_017 crossref_primary_10_1016_j_jinf_2018_06_009 crossref_primary_10_1128_AAC_00190_18 crossref_primary_10_1371_journal_pmed_1003566 crossref_primary_10_1513_AnnalsATS_201509_632PS crossref_primary_10_1586_ecp_09_19 crossref_primary_10_1128_AAC_00105_15 crossref_primary_10_3390_ijms232214461 crossref_primary_10_1016_j_bmc_2015_10_021 crossref_primary_10_1128_CMR_00059_10 crossref_primary_10_1186_1476_0711_13_13 crossref_primary_10_1007_s11904_010_0054_4 crossref_primary_10_1517_14728214_2016_1151000 crossref_primary_10_1128_JCM_00043_12 crossref_primary_10_1345_aph_1Q299 crossref_primary_10_1371_journal_pone_0145066 crossref_primary_10_1111_tmi_13371 crossref_primary_10_1016_j_ejpb_2013_10_019 crossref_primary_10_1164_rccm_201308_1446ED crossref_primary_10_1371_journal_pone_0144136 crossref_primary_10_1517_14656566_2012_657176 crossref_primary_10_1007_s11095_013_1245_7 crossref_primary_10_1016_S1473_3099_23_00067_1 crossref_primary_10_1097_COH_0000000000000009 crossref_primary_10_1016_j_ijantimicag_2013_04_027 crossref_primary_10_1056_NEJMoa2033400 crossref_primary_10_1136_bcr_2017_221938 crossref_primary_10_1007_s40265_018_1043_y crossref_primary_10_1371_journal_pmed_1003059 crossref_primary_10_1128_AAC_02141_13 crossref_primary_10_1016_j_bmc_2015_02_032 crossref_primary_10_1097_MD_0000000000030412 crossref_primary_10_1093_bmb_ldq035 crossref_primary_10_1016_S0992_5945_09_70161_8 crossref_primary_10_1016_S1473_3099_12_70264_5 crossref_primary_10_4137_CMT_S1974 crossref_primary_10_1128_AAC_00064_11 crossref_primary_10_1128_AAC_00989_19 crossref_primary_10_1164_rccm_201007_1126ED crossref_primary_10_1002_ddr_20456 crossref_primary_10_1016_j_medmal_2010_04_004 crossref_primary_10_1007_s00044_012_0074_2 crossref_primary_10_1016_j_cell_2011_02_022 crossref_primary_10_1093_cid_civ612 crossref_primary_10_1016_j_bmcl_2013_07_006 crossref_primary_10_1164_rccm_200906_0863ED crossref_primary_10_5334_aogh_2432 crossref_primary_10_1016_j_ijid_2013_09_013 crossref_primary_10_1371_journal_pone_0154778 crossref_primary_10_1128_JCM_05286_11 crossref_primary_10_1038_s41598_018_24067_x crossref_primary_10_1097_QAD_0b013e32836268f4 crossref_primary_10_1016_j_ijantimicag_2010_03_020 crossref_primary_10_1128_AAC_00829_13 crossref_primary_10_2217_fmb_09_39 crossref_primary_10_1016_S1473_3099_13_70156_7 crossref_primary_10_1371_journal_pone_0159827 crossref_primary_10_1183_16000617_0085_2015 crossref_primary_10_1038_s41598_017_09177_2 crossref_primary_10_1099_jmm_0_024729_0 crossref_primary_10_1128_AAC_00749_10 crossref_primary_10_1016_S1473_3099_18_30480_8 crossref_primary_10_1128_AAC_06288_11 crossref_primary_10_1164_rccm_200901_0078OC crossref_primary_10_7759_cureus_54225 crossref_primary_10_3109_10428194_2012_725848 crossref_primary_10_1016_S0140_6736_12_61080_0 crossref_primary_10_1097_QAI_0b013e31821b4b42 crossref_primary_10_1164_rccm_201410_1843OC crossref_primary_10_1128_AAC_00384_12 crossref_primary_10_3109_1061186X_2015_1009076 crossref_primary_10_1093_infdis_jis041 crossref_primary_10_2165_11593160_000000000_00000 crossref_primary_10_1016_S1473_3099_16_30315_2 crossref_primary_10_1016_j_antinf_2015_07_003 crossref_primary_10_1517_14728214_2011_521497 crossref_primary_10_1093_infdis_jis034 crossref_primary_10_1371_journal_pone_0039754 crossref_primary_10_1016_j_inoche_2023_111453 crossref_primary_10_2165_11538170_000000000_00000 crossref_primary_10_1016_j_ijid_2014_03_1388 crossref_primary_10_1186_s13104_018_3522_3 crossref_primary_10_1016_S0140_6736_09_61188_0 |
| Cites_doi | 10.1164/rccm.200310-1380OC 10.1164/rccm.200603-360OC 10.1016/S0140-6736(02)09742-8 10.1164/rccm.200407-905OC 10.1093/jac/44.3.393 10.1172/JCI34614 10.1128/AAC.42.8.2066 10.1128/AAC.48.3.780-782.2004 10.1093/jac/dki376 10.1164/rccm.200407-885OC 10.1056/NEJMoa055191 10.1164/ajrccm/147.4.1062 10.1128/AAC.45.12.3482-3486.2001 10.1016/S0140-6736(04)17141-9 10.1128/AAC.43.1.85 10.1164/rccm.200305-682OC |
| ContentType | Journal Article |
| Copyright | 2009 Elsevier Ltd Elsevier Ltd 2009 INIST-CNRS Copyright Elsevier Limited Apr 4-Apr 10, 2009 |
| Copyright_xml | – notice: 2009 Elsevier Ltd – notice: Elsevier Ltd – notice: 2009 INIST-CNRS – notice: Copyright Elsevier Limited Apr 4-Apr 10, 2009 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7T2 7X8 |
| DOI | 10.1016/S0140-6736(09)60333-0 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Database eLibrary AUTh Library subscriptions: ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Biological Science Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial Health and Safety Science Abstracts (Full archive) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) Health & Safety Science Abstracts MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology Health & Safety Science Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1189 |
| ExternalDocumentID | 1674727991 19345831 21309824 10_1016_S0140_6736_09_60333_0 S0140673609603330 1_s2_0_S0140673609603330 |
| Genre | Clinical Trial, Phase II Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Brazil Brazil, Rio de Janeiro |
| GeographicLocations_xml | – name: Brazil, Rio de Janeiro – name: Brazil |
| GrantInformation_xml | – fundername: FDA HHS grantid: R01FD002135 – fundername: FDA HHS grantid: R01 FD002135 – fundername: NIAID NIH HHS grantid: K24 AI001637 – fundername: FIC NIH HHS grantid: TW006885 – fundername: FIC NIH HHS grantid: U2R TW006885 – fundername: PHS HHS grantid: 01607 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO .GJ 04C 0R~ 123 1B1 1P~ 1RT 1~5 29L 3EH 3O- 4.4 41~ 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 8WZ 9JM A6W AABNK AAEDT AAEDW AAEJM AAFWJ AAIKJ AAKAS AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABDBF ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ABWVN ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACUHS ACVFH ADBBV ADCNI ADMUD ADNMO ADXHL ADZCM AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFFNX AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AGQPQ AHHHB AHMBA AHQJS AIGII AIIUN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKVCP AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI ARTTT ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 D0S DU5 DWQXO EAP EAS EAU EAZ EBC EBD EBS EBU EFJIC EFKBS EGS EHN EIHBH EJD EMB EMK EMOBN ENC EO8 EO9 EP2 EP3 EPL EPS EPT ESX EVS EWM EX3 F5P FD8 FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IHE J1W J5H K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 MVM N9A NAPCQ O-L O9- OD. OO~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ Q~Q R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ SV3 T5K TEORI TH9 TLN TWZ UAP UBE UHU UKHRP UQL UV1 WOQ WOW WUQ X7M XAX XDU XPP YYM YYQ Z5R ZGI ZMT ZXP ZY4 ~G0 ~HD 3V. 88A AACTN AAYOK ABTAH ACRZS AFCTW AFKWA AJOXV ALIPV AMFUW M0L M41 PKN RIG SDF ABLVK ABYKQ AHPSJ AJBFU NHB XFK Y6R ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7T2 7X8 PUEGO |
| ID | FETCH-LOGICAL-c607t-e7ac43d800be599a6f77115e2ec0c4197a1dba55c5d6e0b4a3eabe918d0ce3f13 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 247 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000264940600032&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Thu Oct 02 11:05:09 EDT 2025 Tue Oct 07 09:22:59 EDT 2025 Tue Oct 07 05:44:50 EDT 2025 Mon Jul 21 05:35:21 EDT 2025 Mon Jul 21 09:16:02 EDT 2025 Sat Nov 29 04:00:01 EST 2025 Tue Nov 18 22:13:37 EST 2025 Fri Feb 23 02:30:15 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Oct 14 19:24:28 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9670 |
| Keywords | Mycobacterial infection Moxifloxacin Infection Medicine Fluoroquinolone derivatives Treatment Tuberculosis Phase II trial Bacteriosis Clinical trial Ethambutol Antituberculous agent Antibacterial agent Quinolone derivatives Comparative study |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-e7ac43d800be599a6f77115e2ec0c4197a1dba55c5d6e0b4a3eabe918d0ce3f13 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/2866651 |
| PMID | 19345831 |
| PQID | 199020885 |
| PQPubID | 40246 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_67118301 proquest_miscellaneous_20538928 proquest_journals_199020885 pubmed_primary_19345831 pascalfrancis_primary_21309824 crossref_primary_10_1016_S0140_6736_09_60333_0 crossref_citationtrail_10_1016_S0140_6736_09_60333_0 elsevier_sciencedirect_doi_10_1016_S0140_6736_09_60333_0 elsevier_clinicalkeyesjournals_1_s2_0_S0140673609603330 elsevier_clinicalkey_doi_10_1016_S0140_6736_09_60333_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-04-04 |
| PublicationDateYYYYMMDD | 2009-04-04 |
| PublicationDate_xml | – month: 04 year: 2009 text: 2009-04-04 day: 04 |
| PublicationDecade | 2000 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2009 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Nuermberger, Yoshimatsu, Tyagi (bib14) 2004; 169 Chang, Leung, Yew, Ho, Tam (bib19) 2004; 170 Kubica, Dye, Cohn, Middlebrook (bib9) 1963; 87 Johnson, Hadad, Boom (bib24) 2006; 10 Nuermberger, Yoshimatsu, Tyagi (bib15) 2004; 170 isoniazid in the first 2 months of treatment for pulmonary tuberculosis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; Sept 17–20, 2007. Abstract L-736-B. (bib3) 2008 Dorman SE, Johnson JJ, Goldberg S, et al. Moxifloxacin Young, Perkins, Duncan, Barry (bib1) 2008; 118 Kent, Kubica (bib10) 1985 Fox, Ellard, Mitchison (bib11) 1999; 3 Dye, Watt, Bleed (bib2) 2002; 80 Lounis, Bentoucha, Truffot-Pernot (bib7) 2001; 45 (bib13) 1978; 118 Mitchison (bib8) 1993; 147 (bib12) 1972; 1 Rustomjee, Lienhardt, Kanyok (bib17) 2008; 12 Gillespie, Gosling, Uiso, Sam, Kanduma, McHugh (bib25) 2005; 56 Pletz, De Roux, Roth, Neumann, Mauch, Lode (bib22) 2004; 48 Miyazaki, Miyazaki, Chen, Chaisson, Bishai (bib6) 1999; 43 Ji, Lounis, Maslo, Truffot-Pernot, Bonnafous, Grosset (bib4) 1998; 42 Gillespie, Billington (bib5) 1999; 44 Jindani, Nunn, Enarson (bib20) 2004; 364 Park-Wyllie, Juurlink, Kopp (bib21) 2006; 354 Burman, Goldberg, Johnson (bib16) 2006; 174 Gosling, Uiso, Sam (bib23) 2003; 168 (bib18) 2002; 360 (10.1016/S0140-6736(09)60333-0_bib13) 1978; 118 Mitchison (10.1016/S0140-6736(09)60333-0_bib8) 1993; 147 Gillespie (10.1016/S0140-6736(09)60333-0_bib25) 2005; 56 Kent (10.1016/S0140-6736(09)60333-0_bib10) 1985 Young (10.1016/S0140-6736(09)60333-0_bib1) 2008; 118 Johnson (10.1016/S0140-6736(09)60333-0_bib24) 2006; 10 Miyazaki (10.1016/S0140-6736(09)60333-0_bib6) 1999; 43 Gillespie (10.1016/S0140-6736(09)60333-0_bib5) 1999; 44 Kubica (10.1016/S0140-6736(09)60333-0_bib9) 1963; 87 Nuermberger (10.1016/S0140-6736(09)60333-0_bib15) 2004; 170 Park-Wyllie (10.1016/S0140-6736(09)60333-0_bib21) 2006; 354 (10.1016/S0140-6736(09)60333-0_bib12) 1972; 1 Jindani (10.1016/S0140-6736(09)60333-0_bib20) 2004; 364 Chang (10.1016/S0140-6736(09)60333-0_bib19) 2004; 170 Fox (10.1016/S0140-6736(09)60333-0_bib11) 1999; 3 Lounis (10.1016/S0140-6736(09)60333-0_bib7) 2001; 45 Rustomjee (10.1016/S0140-6736(09)60333-0_bib17) 2008; 12 10.1016/S0140-6736(09)60333-0_bib26 Gosling (10.1016/S0140-6736(09)60333-0_bib23) 2003; 168 Burman (10.1016/S0140-6736(09)60333-0_bib16) 2006; 174 Nuermberger (10.1016/S0140-6736(09)60333-0_bib14) 2004; 169 (10.1016/S0140-6736(09)60333-0_bib18) 2002; 360 Dye (10.1016/S0140-6736(09)60333-0_bib2) 2002; 80 (10.1016/S0140-6736(09)60333-0_bib3) 2008 Ji (10.1016/S0140-6736(09)60333-0_bib4) 1998; 42 Pletz (10.1016/S0140-6736(09)60333-0_bib22) 2004; 48 19345812 - Lancet. 2009 Apr 4;373(9670):1145. doi: 10.1016/S0140-6736(09)60662-0. 19345815 - Lancet. 2009 Apr 4;373(9670):1148-9. doi: 10.1016/S0140-6736(09)60559-6. 19560596 - Lancet. 2009 Jun 27;373(9682):2197-8; author reply 2198-9. doi: 10.1016/S0140-6736(09)61188-0. |
| References_xml | – volume: 168 start-page: 1342 year: 2003 end-page: 1345 ident: bib23 article-title: The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis publication-title: Am J Respir Crit Care Med – volume: 118 start-page: 1255 year: 2008 end-page: 1265 ident: bib1 article-title: Confronting the scientific obstacles to global control of tuberculosis publication-title: J Clin Invest – volume: 80 start-page: 37 year: 2002 end-page: 44 ident: bib2 article-title: Low access to a highly effective therapy: a challenge for international tuberculosis control publication-title: Bull World Health Organ – volume: 118 start-page: 219 year: 1978 end-page: 228 ident: bib13 article-title: Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report publication-title: Am Rev Respir Dis – volume: 1 start-page: 1079 year: 1972 end-page: 1085 ident: bib12 article-title: Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis publication-title: Lancet – volume: 170 start-page: 1124 year: 2004 end-page: 1130 ident: bib19 article-title: A nested case-control study on treatment-related risk factors for early relapse of tuberculosis publication-title: Am J Respir Crit Care Med – volume: 354 start-page: 1352 year: 2006 end-page: 1361 ident: bib21 article-title: Outpatient gatifloxacin therapy and dysglycemia in older adults publication-title: N Engl J Med – volume: 48 start-page: 780 year: 2004 end-page: 782 ident: bib22 article-title: Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study publication-title: Antimicrob Agents Chemother – volume: 43 start-page: 85 year: 1999 end-page: 89 ident: bib6 article-title: Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis publication-title: Antimicrob Agents Chemother – volume: 3 start-page: S231 year: 1999 end-page: S279 ident: bib11 article-title: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications publication-title: Int J Tuberc Lung Dis – volume: 12 start-page: 128 year: 2008 end-page: 138 ident: bib17 article-title: A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 42 start-page: 2066 year: 1998 end-page: 2069 ident: bib4 article-title: In vitro and in vivo activities of moxifloxacin and clinafloxacin against publication-title: Antimicrob Agents Chemother – reference: isoniazid in the first 2 months of treatment for pulmonary tuberculosis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; Sept 17–20, 2007. Abstract L-736-B. – volume: 169 start-page: 421 year: 2004 end-page: 426 ident: bib14 article-title: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis publication-title: Am J Respir Crit Care Med – year: 2008 ident: bib3 publication-title: Global tuberculosis control 2008—surveillance, planning, financing – volume: 10 start-page: 605 year: 2006 end-page: 612 ident: bib24 article-title: Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 45 start-page: 3482 year: 2001 end-page: 3486 ident: bib7 article-title: Effectiveness of once-weekly rifapentine and moxifloxacin regimens against publication-title: Antimicrob Agents Chemother – volume: 170 start-page: 1131 year: 2004 end-page: 1134 ident: bib15 article-title: Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis publication-title: Am J Respir Crit Care Med – volume: 56 start-page: 1169 year: 2005 end-page: 1171 ident: bib25 article-title: Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis publication-title: J Antimicrob Chemother – volume: 360 start-page: 528 year: 2002 end-page: 534 ident: bib18 article-title: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial publication-title: Lancet – volume: 147 start-page: 1062 year: 1993 end-page: 1063 ident: bib8 article-title: Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months publication-title: Am Rev Respir Dis – volume: 364 start-page: 1244 year: 2004 end-page: 1251 ident: bib20 article-title: Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial publication-title: Lancet – volume: 87 start-page: 775 year: 1963 end-page: 779 ident: bib9 article-title: Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria publication-title: Am Rev Respir Dis – volume: 174 start-page: 331 year: 2006 end-page: 338 ident: bib16 article-title: Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis publication-title: Am J Respir Crit Care Med – volume: 44 start-page: 393 year: 1999 end-page: 395 ident: bib5 article-title: Activity of moxifloxacin against mycobacteria publication-title: J Antimicrob Chemother – reference: Dorman SE, Johnson JJ, Goldberg S, et al. Moxifloxacin – year: 1985 ident: bib10 publication-title: Public health mycobacteriology: a guide or the level III laboratory – volume: 12 start-page: 128 year: 2008 ident: 10.1016/S0140-6736(09)60333-0_bib17 article-title: A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 169 start-page: 421 year: 2004 ident: 10.1016/S0140-6736(09)60333-0_bib14 article-title: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200310-1380OC – year: 1985 ident: 10.1016/S0140-6736(09)60333-0_bib10 – volume: 174 start-page: 331 year: 2006 ident: 10.1016/S0140-6736(09)60333-0_bib16 article-title: Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200603-360OC – volume: 360 start-page: 528 year: 2002 ident: 10.1016/S0140-6736(09)60333-0_bib18 article-title: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial publication-title: Lancet doi: 10.1016/S0140-6736(02)09742-8 – volume: 1 start-page: 1079 year: 1972 ident: 10.1016/S0140-6736(09)60333-0_bib12 article-title: Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis publication-title: Lancet – volume: 170 start-page: 1124 year: 2004 ident: 10.1016/S0140-6736(09)60333-0_bib19 article-title: A nested case-control study on treatment-related risk factors for early relapse of tuberculosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200407-905OC – volume: 44 start-page: 393 year: 1999 ident: 10.1016/S0140-6736(09)60333-0_bib5 article-title: Activity of moxifloxacin against mycobacteria publication-title: J Antimicrob Chemother doi: 10.1093/jac/44.3.393 – volume: 87 start-page: 775 year: 1963 ident: 10.1016/S0140-6736(09)60333-0_bib9 article-title: Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria publication-title: Am Rev Respir Dis – volume: 118 start-page: 1255 year: 2008 ident: 10.1016/S0140-6736(09)60333-0_bib1 article-title: Confronting the scientific obstacles to global control of tuberculosis publication-title: J Clin Invest doi: 10.1172/JCI34614 – volume: 42 start-page: 2066 year: 1998 ident: 10.1016/S0140-6736(09)60333-0_bib4 article-title: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.8.2066 – volume: 48 start-page: 780 year: 2004 ident: 10.1016/S0140-6736(09)60333-0_bib22 article-title: Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.3.780-782.2004 – volume: 80 start-page: 37 year: 2002 ident: 10.1016/S0140-6736(09)60333-0_bib2 article-title: Low access to a highly effective therapy: a challenge for international tuberculosis control publication-title: Bull World Health Organ – volume: 56 start-page: 1169 year: 2005 ident: 10.1016/S0140-6736(09)60333-0_bib25 article-title: Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis publication-title: J Antimicrob Chemother doi: 10.1093/jac/dki376 – volume: 118 start-page: 219 year: 1978 ident: 10.1016/S0140-6736(09)60333-0_bib13 article-title: Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report publication-title: Am Rev Respir Dis – volume: 170 start-page: 1131 year: 2004 ident: 10.1016/S0140-6736(09)60333-0_bib15 article-title: Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200407-885OC – volume: 354 start-page: 1352 year: 2006 ident: 10.1016/S0140-6736(09)60333-0_bib21 article-title: Outpatient gatifloxacin therapy and dysglycemia in older adults publication-title: N Engl J Med doi: 10.1056/NEJMoa055191 – ident: 10.1016/S0140-6736(09)60333-0_bib26 – year: 2008 ident: 10.1016/S0140-6736(09)60333-0_bib3 – volume: 147 start-page: 1062 year: 1993 ident: 10.1016/S0140-6736(09)60333-0_bib8 article-title: Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months publication-title: Am Rev Respir Dis doi: 10.1164/ajrccm/147.4.1062 – volume: 3 start-page: S231 issue: suppl 2 year: 1999 ident: 10.1016/S0140-6736(09)60333-0_bib11 article-title: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications publication-title: Int J Tuberc Lung Dis – volume: 45 start-page: 3482 year: 2001 ident: 10.1016/S0140-6736(09)60333-0_bib7 article-title: Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.45.12.3482-3486.2001 – volume: 364 start-page: 1244 year: 2004 ident: 10.1016/S0140-6736(09)60333-0_bib20 article-title: Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(04)17141-9 – volume: 43 start-page: 85 year: 1999 ident: 10.1016/S0140-6736(09)60333-0_bib6 article-title: Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.43.1.85 – volume: 10 start-page: 605 year: 2006 ident: 10.1016/S0140-6736(09)60333-0_bib24 article-title: Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis publication-title: Int J Tuberc Lung Dis – volume: 168 start-page: 1342 year: 2003 ident: 10.1016/S0140-6736(09)60333-0_bib23 article-title: The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200305-682OC – reference: 19345815 - Lancet. 2009 Apr 4;373(9670):1148-9. doi: 10.1016/S0140-6736(09)60559-6. – reference: 19560596 - Lancet. 2009 Jun 27;373(9682):2197-8; author reply 2198-9. doi: 10.1016/S0140-6736(09)61188-0. – reference: 19345812 - Lancet. 2009 Apr 4;373(9670):1145. doi: 10.1016/S0140-6736(09)60662-0. |
| SSID | ssj0004605 |
| Score | 2.4479046 |
| Snippet | New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a... Summary Background New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone... Background New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1183 |
| SubjectTerms | Adult Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Aza Compounds - adverse effects Aza Compounds - therapeutic use Bacterial diseases Biological and medical sciences Brazil - epidemiology Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Ethambutol - adverse effects Ethambutol - therapeutic use Female Fluoroquinolones General aspects Human bacterial diseases Humans Infectious diseases Internal Medicine Isoniazid - therapeutic use Kaplan-Meier Estimate Logistic Models Male Medical sciences Moxifloxacin Multivariate Analysis Mycobacterium tuberculosis Pyrazinamide - therapeutic use Quinolines - adverse effects Quinolines - therapeutic use Rifampin - therapeutic use Sputum - microbiology Time Factors Treatment Outcome Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - diagnosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology Tuberculosis, Pulmonary - mortality |
| Title | Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673609603330 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673609603330 https://dx.doi.org/10.1016/S0140-6736(09)60333-0 https://www.ncbi.nlm.nih.gov/pubmed/19345831 https://www.proquest.com/docview/199020885 https://www.proquest.com/docview/20538928 https://www.proquest.com/docview/67118301 |
| Volume | 373 |
| WOSCitedRecordID | wos000264940600032&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest_Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest_Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoixAS4v1YCosPHEAi1HGcxOGCoGpFD7usSkG9WY4f6kphs2wS1BO_nbHzWCHtUiQuk-enxPFk5ktm7EHopU14nFpGA0slC5gbxJVbQwLKecJs6FOjfLGJdDrl5-fZrMvNqbq0yt4mekOtS-X-kR-EYDYpvBLx--WPwBWNcsHVroLGDtpzkyREPnNvtmlYpM9wXw_gOfgy7HxFstcJiaIoINtc062lrOCB2bbSxXYq6l3S8Z3_bMxddLvjovhDqzz30DWzuI9uTLpo-wP0a1Jezm1RXkrYxi5_o6mwqS_k97ypywLDTqCPsJiDmSjwkLOOS4vrJjcr1RRlNa_eYYl12eSFCXJgtfoNhjbqEjTMwHqXLF8YjZcX4FPxyQn2tUQeoq_HR2eHn4KuXkOgEpLWgUmlYpEGCpqbOMtkYtMUCKehRhHFwiyVoc5lHKtYJ4bkTEZG5iYLuSbKRDaMHqHdRbkwTxDmkXOcJJJMxkwZybUiMkxUDH4i15aOEOu7SqhuMnNXU6MQG7LWSCZ8DwsyQm8H2LKdzeMqQNLrgeiHqoJxFeBvrgKmm4Cm6kxEJUJRUUFatAO7b0mAApIPyI4FtezmXy46_kNVhzZSYCoZp2yE9nt9FOsb6ZVxhF4MR0EFXORILkzZVIKCqeYZ5dvPSKCnXaeN0OP2lVg_3yxysfnw6V-vvY9u9nE6wp6h3XrVmOfouvpZz6vVGO2kp9-cPE-95CD5YThGex-PprNT2JqQVp45SSdefvZyNvZW4TeiPFqC |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQICEuF_KYPMDSCAR5jhO4iAhhIBp1dYKiU7am3F80SqFpjQJjBf-Ef-R49wqpJbxsgee2qb9msY-ly_1d3wQemIjHsaWUc9SyTzmirhSa4hHOY-Y9WtpVN1sIh6P-fFx8nED_epqYZyssouJdaDWuXL_ke_6EDYpuET4Zv7Vc02j3OJq10GjsYoD8-M73LEVr4fvYXqfUrr3YfJu32ubCngqInHpmVgqFmjgSakJk0RGNo6BFRlqFFHMT2Lp61SGoQp1ZEjKZGBkahKfa6JMYP0AvvcCuui21XMKwhGZrCrDrBX1y4Kh3U_9wWckeR6RIAg8si4VXpvLAibINp011lPfOgXu3fjPBu8mut5ybfy2cY5baMPMbqPLo1ZNcAf9HOWnU5vlpxJeY6dPqQpsyhP5Ja3KPMNwEOgxPEwhDGa41-Tj3OKySs1CVVleTItXWGKdV2lmvBRYu36BYUx1Dh5k4HlbDJAZjecnwBnwcIjrXil30dG5XP09tDnLZ-YBwjxwxIAEksmQKSO5VkT6kQohD6ba0gFinWkI1W7W7nqGZGKFKo8korYoQQboZQ-bN7uVnAWIOrsTXSkuJA8B-fQsYLwKaIo2BBbCFwUVpEE7sLtXBiggeY9sWV7D3v7lpNt_uEZ_jRSYWMIpG6Ctzv7F8od0xj9AO_27YAJuZUzOTF4VgkIq4gnl6z8RwUy7SRug-40LLsc3CZz2wH_413PvoCv7k9GhOByOD7bQ1W5NkrBHaLNcVOYxuqS-ldNisV3HFIw-n7cf_gZzIq_T |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMS4n4pg80PIIG0UMd2EgcJIbRRUY1VkwBpb8ZxbK1SaEqTwHjhf_HvOM6tQmoZL3vgqW3Sr0nsc_lSfycHoSc2FEFkOfUsVdzjrogrsYZ4VIiQW7-WRtXNJqLJRJycxMcb6FdXC-NklV1MrAN1mmv3H_nQh7BJwSWCoW1VEccHo9fzr55rIOUWWrtuGo2FHJof3-HurXg1PoCpfkrp6O3H_Xde22DA0yGJSs9ESnOWAmdKTBDHKrRRBAzJUKOJ5n4cKT9NVBDoIA0NSbhiRiUm9kVKtGHWZ_C7l9DliIERuyL1fX9VSWatrl8WDw0_9Bufkfh5SBhjHlmXFq_NVQGTZZsuG-tpcJ0ORzf-44G8ia63HBy_aZzmFtows9to66hVGdxBP4_ys6nN8jMFn7HTrVQFNuWp-pJUZZ5h2Ai0GV6mEB4z3Gv1cW5xWSVmoassL6bFS6xwmldJZrwE2Hy6h2F80xw8y8D7tkggMymenwKXwOMxrnuo3EWfLuTq76HNWT4zDxAWzBEGwhRXAddGiVQT5Yc6gPyYpJYOEO_MROr2Ie6ul0gmV6j1SCxr65JkgF70sHnzFJPzAGFng7Ir0YWkIiHPngeMVgFN0YbGQvqyoJI0aAd299AABaTokS37a1jdvxx05w836a-RAkOLBeUDtN35glyeSOcIA7Tb7wUTcCtmambyqpAUUpSIqVj_jRBm2k3aAN1v3HE5vjFzmgT_4V-PvYu2wP3k-_HkcBtd7ZYqCX-ENstFZR6jK_pbOS0WO3V4wejzRbvhb6A_uFE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Moxifloxacin+versus+ethambutol+in+the+initial+treatment+of+tuberculosis%3A+a+double-blind%2C+randomised%2C+controlled+phase+II+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Conde%2C+Marcus+B&rft.au=Efron%2C+Anne&rft.au=Loredo%2C+Carla&rft.au=De+Souza%2C+Gilvan+R+Muzy&rft.date=2009-04-04&rft.issn=1474-547X&rft.eissn=1474-547X&rft.volume=373&rft.issue=9670&rft.spage=1183&rft_id=info:doi/10.1016%2FS0140-6736%2809%2960333-0&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673609X6068X%2Fcov150h.gif |